| B-cell depletion with rituximab in relapsing–remitting multiple sclerosis SL Hauser, E Waubant, DL Arnold, T Vollmer, J Antel, RJ Fox, A Bar-Or, ... New England Journal of Medicine 358 (7), 676-688, 2008 | 2857 | 2008 |
| Ocrelizumab versus placebo in primary progressive multiple sclerosis X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ... New england journal of medicine 376 (3), 209-220, 2017 | 2125 | 2017 |
| Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis R Gold, L Kappos, DL Arnold, A Bar-Or, G Giovannoni, K Selmaj, ... New England Journal of Medicine 367 (12), 1098-1107, 2012 | 2123 | 2012 |
| Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ... New England Journal of Medicine 376 (3), 221-234, 2017 | 2041 | 2017 |
| IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases P Shen, T Roch, V Lampropoulou, RA O’Connor, U Stervbo, E Hilgenberg, ... Nature 507 (7492), 366-370, 2014 | 1177 | 2014 |
| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 1077 | 2018 |
| Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial L Kappos, D Li, PA Calabresi, P O'Connor, A Bar-Or, F Barkhof, M Yin, ... The Lancet 378 (9805), 1779-1787, 2011 | 970 | 2011 |
| Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis M Duddy, M Niino, F Adatia, S Hebert, M Freedman, H Atkins, HJ Kim, ... The Journal of Immunology 178 (10), 6092-6099, 2007 | 795 | 2007 |
| B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells TA Barr, P Shen, S Brown, V Lampropoulou, T Roch, S Lawrie, B Fan, ... Journal of Experimental Medicine 209 (5), 1001-1010, 2012 | 743 | 2012 |
| Ofatumumab versus teriflunomide in multiple sclerosis SL Hauser, A Bar-Or, JA Cohen, G Comi, J Correale, PK Coyle, AH Cross, ... New England Journal of Medicine 383 (6), 546-557, 2020 | 635 | 2020 |
| Abnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS? A Bar‐Or, L Fawaz, B Fan, PJ Darlington, A Rieger, C Ghorayeb, ... Annals of neurology 67 (4), 452-461, 2010 | 627 | 2010 |
| Rituximab in relapsing‐remitting multiple sclerosis: a 72‐week, open‐label, phase I trial A Bar‐Or, PAJ Calabresi, D Arnold, C Markowitz, S Shafer, LH Kasper, ... Annals of neurology 63 (3), 395-400, 2008 | 614 | 2008 |
| Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays PJ Waters, A McKeon, MI Leite, S Rajasekharan, VA Lennon, A Villalobos, ... Neurology 78 (9), 665-671, 2012 | 606 | 2012 |
| Comparison of polarization properties of human adult microglia and blood‐derived macrophages BA Durafourt, CS Moore, DA Zammit, TA Johnson, F Zaguia, MC Guiot, ... Glia 60 (5), 717-727, 2012 | 566 | 2012 |
| Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions B Banwell, A Ghezzi, A Bar-Or, Y Mikaeloff, M Tardieu The Lancet Neurology 6 (10), 887-902, 2007 | 524 | 2007 |
| Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy SA Apostolidis, M Kakara, MM Painter, RR Goel, D Mathew, K Lenzi, ... Nature medicine 27 (11), 1990-2001, 2021 | 485 | 2021 |
| A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis JM Burton, S Kimball, R Vieth, A Bar-Or, HM Dosch, R Cheung, D Gagne, ... Neurology 74 (23), 1852-1859, 2010 | 485 | 2010 |
| Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis A Bar‐Or, RK Nuttall, M Duddy, A Alter, HJ Kim, I Ifergan, CJ Pennington, ... Brain 126 (12), 2738-2749, 2003 | 478 | 2003 |
| Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease A Monsonego, V Zota, A Karni, JI Krieger, A Bar-Or, G Bitan, AE Budson, ... The Journal of clinical investigation 112 (3), 415-422, 2003 | 472 | 2003 |
| A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses PW O’connor, D Li, MS Freedman, A Bar-Or, GPA Rice, C Confavreux, ... Neurology 66 (6), 894-900, 2006 | 463 | 2006 |
Ludwig KapposUniversity of Basel and Research Center of Clinical Neuroimmunology and Neuroscience Basel (RC2NB)Zweryfikowany adres z uhbs.ch
